TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04186624

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subacromial-subdeltoid bursa corticosteroid injection
Description: 1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Subacromial-subdeltoid bursa corticosteroid injection
Description: 1 ml (7 mg / ml) betamethasone and 4 ml of 0.5% bupivacaine will be given subacromial bursa-subdeltoid space. Injection will be performed ultrasound-guided while the patient is in sitting position with the lateral approach.
Study: NCT02044653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GX-E2
Description: Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NESP
Description: Each Group of Hemodialysis (n=30) will be administered NESP 30ug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MIRCERA
Description: Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
Study: NCT01965314

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Simulation based training
Description: In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional training
Description: Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Traditional training
Description: Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
Study: NCT02489240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin D3 tablets
Description: 2000 IU vitamin D3 tablets were taken daily for 6 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2000 IU placebo tablets were taken daily for 6 days
Study: NCT05409716

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Compressive Elastic dressing for hemostasis in cardiac procedure using radial approach
Description: Following cardiac procedure using radial approach, compressive elastic dressing, standardized as 13 threads gauze overlapped, opened, longitudinally pleated once and wrapped, making a 5-cm long cylinder, 1-cm in height, fixed with elastic crepe bandage was used to achieve hemostasis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Wristband TR band for hemostasis in cardiac procedure using radial approach
Description: Following cardiac procedure using radial approach, hemostatic wristband TR BandR (Terumo Corporation, Tokyo, Japan) was utilized was used to achieve hemostasis.
Study: NCT03577379

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole Blood Fibrin Clot
Description: For all patients assigned to the treatment group, 35mL of whole blood will be obtained during surgery by an anesthesiologist. 5 mL of the blood will be sent for pre-clot formation cell count evaluation for platelets, red blood cells and white blood cells. The remaining 30mL will be placed into a sterile container with a sintered glass cylinder supported by the lid for fibrin clot formation. The clot formation cups will be placed on a rotator at room temperature for 10 minutes at 125rpm. The fibrin clot will be removed and 5mL of the post-clot serum sent for post-clot formation cell count evaluation for platelets, red blood cells, and white blood cells.
Study: NCT03108066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3795
Description: 800 mg twice daily (four 200 mg oral tablets twice daily)
Study: NCT04726111

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens specific for the study
Description: Specimens (blood, umbilical cord, umbilical cord blood, placenta)

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens specific for the study
Description: Specimens (blood, umbilical cord, umbilical cord blood, placenta)

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens specific for the study
Description: Specimens (blood, umbilical cord, umbilical cord blood, placenta)

Intervention type: OTHER
Group type: OTHER
Intervention: Specimens specific for the study
Description: Specimens (blood, umbilical cord, umbilical cord blood, placenta)
Study: NCT02757625

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine hydrochloride
Description: * 45 weeks CGA to \< 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state~* 6 years old to \< 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state
Study: NCT03571685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sustainable Early Episode Clinic Model of Care
Description: The first 8 weeks is the education phase. Participants attend classes every week for up to 6 hours. From 9 weeks to 10 months participants attend classes for 5 hours every other week. Based on individual progress. Participants can move to the maintenance phase. This phase provides minimal intervention but ongoing support/evaluation.
Study: NCT02095197

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone 80mg
Description: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.

Intervention type: DRUG
Group type: OTHER
Intervention: Triamcinolone 80mg
Description: C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
Study: NCT03278236

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TRF
Description: Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
Study: NCT02406963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Photograph
Description: A digital photograph sent by the family of the surgical site

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telephone Call
Description: Standard telephone call with the nurse practitioner

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Call
Description: Standard telephone call with the nurse practitioner
Study: NCT03327285

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: C-CAR011
Description: CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
Study: NCT00293852

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Outpatient clinic follow-up
Study: NCT04410471

Intervention type: DIAGNOSTIC_TEST
Intervention: CLIA of IgG and IgM against SARS-Cov-2
Description: Report of clinical data

Intervention type: DIAGNOSTIC_TEST
Intervention: CLIA of IgG and IgM against SARS-Cov-2
Description: Report of clinical data
Study: NCT00257738

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAGE-A3
Description: Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HPV-16 vaccine
Description: Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
Study: NCT02775292

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine
Description: Given ID

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies
Study: NCT03456687

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exenatide
Description: Exenatide will be administered through a subcutaneous injection once per week for the duration of the study (1 year).
Study: NCT01488747

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coromega Omega-3 Squeeze
Description: 660 mg EPA, 434 mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coromega Nectar
Description: 660 mg EPA, 436 mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Barleans Swirl
Description: 660 mg EPA, 660 mg DHA

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nordic Omega-3 Softgel
Description: 660 mg EPA, 440 mg DHA
Study: NCT02943187

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive training
Description: A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
Study: NCT01033630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D&G 2g
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D&G 1g
Description: Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Image-matched placebo, made with starch.
Study: NCT01460602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTD of Velcade, Nipent and Rituxan established in Part 1
Description: One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTD of Velcade, Nipent and Rituxan established in Part 1
Description: One of the following dose levels will be chosen and used in Part 2:~1. (VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~2. (VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~3. (VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1~4. (VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
Study: NCT03730376

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cost Information
Description: participants will be given information on the personal and societal costs
Study: NCT00217581

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Must be administered 1st before Docetaxel \& Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
Study: NCT04420169

Intervention type: OTHER
Intervention: Questionnaire
Description: A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients

Intervention type: OTHER
Intervention: Questionnaire
Description: A digital questionnaire to evaluate the communication by midwives will be send out to IVF patients
Study: NCT01343537

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuro Monitoring
Description: Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
Study: NCT04441632

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Positive feedback
Description: Participants will submit positive feedback comments to their colleagues (anonymously or signed, participant-dependent) through an anonymous survey link, a minimum of twice weekly to 6 uniquely different individuals over a 4 week period (total minimum 24 unique individuals over the study period).
Study: NCT02020135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PSMA ADC
Description: Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
Study: NCT01909973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedLink System
Description: Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.
Study: NCT01963507

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
Study: NCT04091737

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734
Description: * Cryopreserved formulated autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734 in a bag for infusion~* Plerixafor to mobilize hematopoietic stem cells prior to each apheresis~* Single dose melphalan before administration of CSL200
Study: NCT04452552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Description: balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: healthy diet
Description: balanced diet program which ranged from 1600 kcal to 2000 kcal/day, which was calculated in an individual basis for each woman according to her basal metabolic rate (BMR) for 8 weeks
Study: NCT01540981

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: MIST Therapy
Description: FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of Care consists of pressure relief, wound cleansing and dressing as needed
Study: NCT05285787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPN-701 (Oral)
Description: MK-7
Study: NCT00934245

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Trivalent Influenza Vaccine
Description: Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated polio vaccine (IPV)
Description: Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
Study: NCT02363712

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: APOS shoe
Description: It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-APOS shoe
Description: It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
Study: NCT00760487

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof Toric IOL
Description: Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
Study: NCT04335058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin + Iron Supplement
Description: Lactoferrin 100 mg twice daily +oral iron

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron Supplement
Description: Oral iron supplement alone
Study: NCT04425681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osimertinib
Description: Treatment of LM With osimertinb

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Treatment of LM With Bevacizumab
Study: NCT02608242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YH22189

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Twynsta 80/10mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crestor 20mg
Study: NCT04121455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaptesed pegol
Description: Olaptesed pegol continuous i.v. administration
Study: NCT03876470

Intervention type: OTHER
Intervention: Hepatitis C treatment as chosen by provider
Description: Participants' providers will determine the type of HCV treatment as appropriate.